Pancreatic Cancer Research

Clinical trialPhase 2Terminated

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

A Phase IIa (Pilot) Study of Neoadjuvant Chemotherapy With Folinic Acid, 5-FU, Irinotecan and Oxaliplatin (FOLFIRINOX) With Digoxin in Patients With Resectable Pancreatic Cancer

Outcome
Stopped early. Results posted; single-arm, no comparisonDue to low accrual and futility (Efficacy or futility)
Phase
Phase 2
Status
Terminated
Study type
Interventional
Start
12 February 2021
Ended
13 May 2025
Enrollment
11 participants
Sites
1
Primary outcomes
Number of Patients Able to Undergo Resection Surgery
Sponsor type
Academic / other
Results posted
21 October 2026
Last update
21 October 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 21 October 2026
Primary outcome
Number of Patients Able to Undergo Resection SurgeryTreatment: 4 of 7Values: ParticipantsTime frame: 16 weeksNo analysis posted for this outcome (outcome 1)
Participants
Treatment: 11 started, 4 completed
Serious adverse events
Treatment: 1 of 7Participants with at least one serious adverse event, of those at risk, as posted
1 secondary outcome
Number of Subjects With Grade 4 Thrombocytopenia and Grade 3-4 Diarrhea
Grade 3-4 Diarrhea: Treatment 1, n=7 [participants] (first of 2 rows)

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to determine the feasibility and safety of combining digoxin as a modulator of the hypoxia pathway in combination with FOLinic acid, 5-Fluorouracil, IRINotecan and OXaliplatin (FOLFIRINOX) in participants with resectable pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

Participants with resectable pancreatic cancer will be treated with oxaliplatin 85 mg/m² IV over 2 hours, irinotecan 150 mg/m² given concurrently with folinic acid 400 mg/m² IV over 90 min, followed by a 46-hour infusion of 5-fluorouracil 2400 mg/m². Slow oral digitalization will be used starting with a daily dose of 0.125 (participants over age 65) or 0.25 mg (participants 65 or younger) per mouth daily. A steady-state will be achieved after five half-lives, which is about 7 to 10 days in the average participant. The initial blood level will be obtained one week after starting digoxin. Assuming the digoxin level is at steady-state and the renal function is stable, there is a linear relationship between digoxin dose and serum concentration. The target digoxin level is between 0.8 to 1.2 ng/mL. Participants will receive IV chemotherapy at 2 week intervals. Re-staging imaging will be performed after 4 doses. If the participants has stable or responsive disease, an additional 4 doses will be given followed by re-staging imaging. The participant will then undergo surgical exploration \~ 4 weeks after the last dose of chemotherapy. The primary endpoint is clinical toxicity. Other endpoints are status of pathologic margins, response rate, pathologic stage, progression-free survival, and overall survival. The correlative endpoint is baseline exome sequencing of circulating cell free tumor DNA. Measurement of quantity of circulating cell free tumor DNA at 4 week intervals while on chemotherapy and prior to surgery; resume at 3 month intervals after surgery. Genomic DNA will be collected at baseline for pharmacogenetic studies of polymorphisms that may be pertinent for the drugs used in the study. Blood will be collected for analysis of possible biomarkers of response to digoxin modulation.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Number of Patients Able to Undergo Resection Surgery [16 weeks]. Count Of Participants, Participants. Treatment (n=7): 4.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Subjects With Grade 4 Thrombocytopenia and Grade 3-4 Diarrhea [16 weeks]. Number, participants. Grade 3-4 Diarrhea: Treatment (n=7): 1. Grade 4 Thrombocytopenia: Treatment (n=7): 0.